GO:0002947 tumor necrosis factor receptor superfamily complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002947 (tumor necrosis factor receptor superfamily complex) is a cellular component defined as a receptor complex containing one or more members of the TNF receptor superfamily.
• TNF receptor superfamily (TNFRSF) complexes are trimeric cell-surface receptors that are activated by trimeric TNF superfamily ligands and control NF-kB, MAPK, and cell-death signaling.
• The complex includes receptors such as TNFRSF1A, TNFRSF1B, FAS, TNFRSF10A/B, TNFRSF5 (CD40), TNFRSF9 (4-1BB), TNFRSF4 (OX40), TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF25 (DR3).
• Assembly of post-receptor signaling complexes (e.g., TRADD, TRAF2, RIPK1, FADD, caspase-8) determines whether the outcome is survival, inflammation, or apoptosis.
• Dysregulated TNFRSF complex signaling is implicated in autoimmune diseases, chronic inflammation, and cancer, making these complexes major therapeutic targets.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of individual TNFRSF components and their signaling outputs.
Description
The tumor necrosis factor receptor superfamily complex (GO:0002947) is a cellular component defined in QuickGO as a receptor complex that contains one or more members of the tumor necrosis factor (TNF) receptor superfamily. These complexes are trimeric transmembrane receptors that bind trimeric TNF superfamily ligands and convert extracellular cues into intracellular signals controlling inflammation, immunity, proliferation, and cell death. Because the same receptor complex can trigger opposing outcomes depending on its composition and post-receptor assembly, TNFRSF complexes are central to both normal immune homeostasis and disease pathogenesis. Researchers study GO:0002947 to understand how receptor stoichiometry, ligand valency, and adaptor recruitment dictate signaling fate, and to design biologics or cell therapies that selectively tune these outputs. The term is therefore a key node linking structural biology, signal transduction, and translational immunology.
tumor necrosis factor receptor superfamily complex At A Glance
| GO ID | GO:0002947 |
|---|---|
| GO term | tumor necrosis factor receptor superfamily complex |
| Ontology | cellular_component |
| Synonym | TNF receptor superfamily complex |
| Definition | A receptor complex that contains one or more members of the tumor necrosis factor (TNF) receptor superfamily. |
| Major function | Ligand-activated receptor platform for TNF superfamily signaling, controlling NF-kB, MAPK, and cell-death pathways. |
| Representative subunits | TNFRSF1A, TNFRSF1B, FAS, TNFRSF10A/B, CD40, 4-1BB, OX40, TACI, BCMA, DR3. |
| Key adaptors | TRADD, TRAF2, RIPK1, FADD, caspase-8. |
| Disease relevance | Autoimmunity, chronic inflammation, and cancer. |
What Is GO:0002947?
GO:0002947 describes a receptor complex whose constituent subunits belong to the TNF receptor superfamily. In practice, this means a membrane-associated assembly of one or more TNFRSF proteins (for example TNFRSF1A, FAS, or CD40) that forms the functional receptor unit for TNF superfamily ligands. The complex is not a single fixed entity; its composition can vary by cell type and context, and it serves as the platform for recruiting intracellular adaptors that initiate downstream signaling.
Why Is tumor necrosis factor receptor superfamily complex Important in Cell Biology?
GO:0002947 matters because TNF receptor superfamily complexes are among the most therapeutically validated signaling hubs in immunology and oncology. They translate extracellular TNF-like ligands into diverse cellular outcomes, including NF-kB-driven survival and inflammation, MAPK-mediated activation, and caspase-dependent apoptosis. Because different TNFRSF members can share ligands yet produce distinct effects, understanding the exact composition and assembly of these complexes is essential for interpreting disease mechanisms and for engineering selective agonists or antagonists.
• TNFRSF complexes are primary sensors of TNF superfamily cytokines and control innate and adaptive immunity.
• They determine cell fate decisions between survival, proliferation, and apoptosis through adaptor selection.
• Dysregulated TNFRSF signaling contributes to autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis.
• Several TNFRSF members are direct targets of approved or investigational biologics and cell therapies.
• The complex is a model system for studying trimeric receptor assembly and ligand valency effects.
• CRISPR-based editing of TNFRSF genes enables causal testing of receptor function in disease models.
• TNFRSF complexes are relevant to cancer immunotherapy, including CAR-T costimulation and checkpoint biology.
• Structural and signaling studies of GO:0002947 inform rational design of receptor-selective therapeutics.
What Happens During tumor necrosis factor receptor superfamily complex?
Ligand binding and receptor trimerization
In simple terms: TNF-like ligands grab and pull together three receptor subunits, switching the receptor on.
TNF superfamily ligands are trimeric and bind TNFRSF complexes to induce receptor trimerization or higher-order clustering, which is the initiating event for signaling. This ligand-induced assembly is a general feature of the superfamily and underlies the activation of receptors such as TNFRSF1A and FAS.
Recruitment of intracellular adaptors
In simple terms: Once activated, the receptor tail recruits adaptor proteins that relay the signal inside the cell.
Activated TNFRSF complexes assemble post-receptor signaling complexes by recruiting adaptors such as TRADD, TRAF2, RIPK1, FADD, and caspase-8. The specific adaptor set determines whether the complex signals survival, inflammation, or death.
NF-kB and MAPK activation
In simple terms: The adaptors turn on transcription factors and kinases that change gene expression.
A major output of TNFRSF complex signaling is activation of NF-kB and MAPK pathways, which drive inflammatory and survival gene programs. These pathways are central to T cell priming and effector function.
Cell death signaling
In simple terms: Some TNFRSF complexes can instead trigger programmed cell death.
Certain TNFRSF complexes, such as those containing FAS or TNFRSF10A/B, recruit FADD and caspase-8 to initiate apoptosis. The balance between survival and death signaling is a key determinant of cellular outcome.
Signal diversification by complex composition
In simple terms: Different receptor combinations produce different biological effects.
Because GO:0002947 encompasses complexes with one or more TNFRSF members, the identity and stoichiometry of subunits diversify signaling outcomes across cell types. This compositional flexibility is exploited in therapeutic design of receptor-selective agonists and antagonists.
Key Genes Involved in GO:0002947 tumor necrosis factor receptor superfamily complex
The following genes encode representative TNF receptor superfamily proteins and signaling components that form or act within GO:0002947 complexes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFRSF1A | Prototype TNF receptor; binds TNF-alpha and activates NF-kB and death signaling | Model for ligand-induced trimerization and dual survival/death output |
| TNFRSF1B | TNF receptor that modulates inflammatory and immune responses | Studied for differential signaling versus TNFRSF1A |
| FAS | Death receptor that triggers apoptosis upon ligand binding | Key model for caspase-8-dependent death complex assembly |
| TNFRSF10A | TRAIL receptor involved in apoptosis induction | Target for cancer cell death studies |
| TNFRSF10B | TRAIL receptor involved in apoptosis induction | Target for cancer cell death studies |
| TNFRSF5 | CD40 receptor controlling B cell and antigen-presenting cell activation | Model for costimulatory signaling and immunotherapy |
| TNFRSF9 | 4-1BB costimulatory receptor on T cells | Used in CAR-T costimulation design |
| TNFRSF4 | OX40 costimulatory receptor on T cells | Studied for T cell priming and effector function |
| TNFRSF13B | TACI receptor regulating B cell and plasma cell biology | Relevant to autoantibody and mucosal immunity |
| TNFRSF17 | BCMA receptor controlling plasma cell survival | Target for myeloma and autoimmune cell therapies |
| TNFRSF25 | DR3 receptor involved in T cell and inflammatory responses | Linked to TL1A signaling in autoimmune disease |
| TRADD | Adaptor recruited to activated TNFRSF1A | Central to post-receptor complex assembly |
| TRAF2 | E3 ligase adaptor mediating NF-kB and MAPK activation | Key node in TNFRSF signaling |
| RIPK1 | Kinase adaptor controlling NF-kB and cell death | Determines survival versus death outcome |
| FADD | Death domain adaptor for caspase activation | Essential for death receptor signaling |
| CASP8 | Initiator caspase in death receptor complexes | Effector of TNFRSF-mediated apoptosis |
| TNFSF15 | TL1A ligand for DR3 | Linked to inflammatory autoimmune diseases |
| TNF | Prototype ligand for TNFRSF1A/1B | Central to inflammation and therapeutic targeting |
How Is tumor necrosis factor receptor superfamily complex Regulated?
TNFRSF complex signaling is regulated at multiple levels, including ligand availability, receptor expression, and post-receptor adaptor modification. Ubiquitination and phosphorylation of adaptors such as TRAF2 and RIPK1 control the switch between NF-kB activation and cell death. In T cells, costimulatory TNFRSF members modulate priming and effector function, providing context-dependent regulation. Therapeutic antagonists and agonists can also tune complex activity, as shown by target-conditioned design of TNFR superfamily binders.
tumor necrosis factor receptor superfamily complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFRSF25 | Inflammatory autoimmune diseases via TL1A signaling | Knockout or point-mutation T cell models |
| TNFRSF1A | Chronic inflammation and autoimmunity | Knockout and knock-in reporter models |
| FAS | Apoptosis dysregulation and autoimmunity | Point-mutation and knockout cell lines |
| TNFRSF17 | Plasma cell malignancies and autoantibody disease | CAR-T and knockout models |
| TNFRSF9 | Cancer immunotherapy costimulation | Overexpression and knock-in CAR models |
Autoimmune and inflammatory diseases
TNFRSF complex signaling is a major driver of chronic inflammation and autoimmunity. TL1A (TNFSF15) and its receptor DR3 (TNFRSF25) are implicated in inflammatory autoimmune diseases, and the pathway is reviewed as a therapeutic target. Dysregulated TNFRSF1A signaling contributes to persistent inflammatory responses.
Cancer
TNF superfamily signaling has dual roles in cancer, promoting either tumor cell survival or death depending on receptor context. Death receptors such as FAS and TNFRSF10A/B can induce apoptosis, while costimulatory receptors such as 4-1BB and OX40 enhance antitumor immunity.
Cell therapy and engineered receptors
TNFRSF complexes are directly relevant to engineered cell therapies. Chimeric antigen receptor T cells have been reengineered for targeted therapy of autoimmune disease, illustrating how receptor signaling modules can be repurposed. Costimulatory domains derived from TNFRSF members such as 4-1BB are used in CAR design.
From tumor necrosis factor receptor superfamily complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a TNFRSF member alter NF-kB activation? | CRISPR knockout cell line |
| Does a disease-associated point mutation change signaling? | CRISPR point-mutation knock-in |
| Where is the receptor complex localized? | Tagged knock-in with fluorescent tag |
| Does overexpression drive ligand-independent signaling? | CRISPR overexpression model |
| Which adaptors are required for death signaling? | Knockout of TRADD, FADD, or CASP8 |
| Can receptor signaling be tuned therapeutically? | Engineered receptor and CAR-T models |
How to Study the tumor necrosis factor receptor superfamily complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect of a TNFRSF gene | Testing requirement for signaling |
| CRISPR point mutation | Effect of a specific residue change | Modeling disease variants |
| NF-kB reporter assay | Transcription factor activation | Measuring receptor signaling output |
| Apoptosis assay | Cell death induction | Death receptor function |
| Co-immunoprecipitation | Protein complex composition | Adaptor recruitment |
| Mass spectrometry | Interactome of activated receptor | Post-receptor complex assembly |
| Fluorescence imaging | Receptor localization and clustering | Membrane assembly studies |
| Structural biology | Ligand-receptor trimer architecture | Mechanistic understanding |
CRISPR knockout and point-mutation screens
CRISPR knockout and point-mutation approaches allow causal testing of individual TNFRSF genes and signaling residues. These methods can identify which components of GO:0002947 complexes are required for specific outputs such as NF-kB activation or apoptosis.
Signaling assays and reporter systems
NF-kB and MAPK reporter assays, together with apoptosis assays, measure the functional consequences of TNFRSF complex activation. These readouts are used to compare wild-type and edited receptors.
Proteomics and interactomics
Affinity purification and mass spectrometry can define the composition of post-receptor signaling complexes assembled on activated TNFRSF receptors, including TRADD, TRAF2, and RIPK1.
Imaging and structural analysis
Fluorescence imaging of tagged receptors and structural studies of ligand-receptor complexes reveal how trimerization and clustering occur at the membrane.
How CRISPR Can Be Used to Study GO:0002947 tumor necrosis factor receptor superfamily complex
Knockout
CRISPR knockout of a TNFRSF gene removes the receptor subunit from the complex, enabling loss-of-function analysis of downstream NF-kB, MAPK, and death signaling. Knockout of adaptors such as TRADD or FADD can dissect post-receptor assembly.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to test the function of individual residues in ligand binding, trimerization, or adaptor recruitment within GO:0002947 complexes.
Knock-in
Knock-in of tags or reporters at endogenous TNFRSF loci allows visualization and biochemical isolation of native receptor complexes without overexpression artifacts.
Overexpression
CRISPR-mediated overexpression can test whether increased receptor levels drive ligand-independent or enhanced signaling, which is relevant to disease-associated overexpression.
How EDITGENE Supports tumor necrosis factor receptor superfamily complex Research
Researchers studying tumor necrosis factor receptor superfamily complex-related genes often need to determine whether a candidate gene is causally involved in receptor assembly, signaling output, or disease phenotypes. EDITGENE provides publication-ready CRISPR models and screening services to test these hypotheses directly.
Contact EDITGENE today to design your custom CRISPR model for tumor necrosis factor receptor superfamily complex research.
Frequently Asked Questions About tumor necrosis factor receptor superfamily complex
What is GO:0002947?
GO:0002947 is the Gene Ontology cellular component term for tumor necrosis factor receptor superfamily complex, defined as a receptor complex containing one or more members of the TNF receptor superfamily.
What genes are involved in the tumor necrosis factor receptor superfamily complex?
Representative genes include TNFRSF1A, TNFRSF1B, FAS, TNFRSF10A, TNFRSF10B, TNFRSF5, TNFRSF9, TNFRSF4, TNFRSF13B, TNFRSF17, and TNFRSF25, along with adaptors such as TRADD, TRAF2, RIPK1, FADD, and CASP8.
What does the TNF receptor superfamily complex do?
It binds trimeric TNF superfamily ligands and initiates intracellular signaling that controls NF-kB, MAPK, inflammation, survival, and apoptosis.
Why is the TNF receptor superfamily complex important in disease?
Dysregulated signaling through these complexes is implicated in autoimmune diseases, chronic inflammation, and cancer.
How is the TNF receptor superfamily complex activated?
Ligand-induced trimerization or clustering of receptor subunits triggers recruitment of intracellular adaptors and downstream signaling.
What is the difference between TNFRSF1A and TNFRSF1B?
Both bind TNF, but they differ in expression, adaptor usage, and downstream signaling outcomes, which is studied using receptor-specific models.
Can CRISPR be used to study TNF receptor superfamily complexes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of receptor and adaptor function.
What adaptors assemble on TNF receptor superfamily complexes?
Key adaptors include TRADD, TRAF2, RIPK1, FADD, and caspase-8, which determine survival versus death signaling.
Which TNFRSF members are used in CAR-T therapy?
Costimulatory domains such as 4-1BB (TNFRSF9) are used in CAR design, and BCMA (TNFRSF17) is a target in cell therapies.
How can I model TNF receptor superfamily complex signaling in the lab?
Common approaches include CRISPR-edited cell lines, NF-kB and apoptosis reporter assays, co-immunoprecipitation, and imaging of tagged receptors.
Conclusion
GO:0002947, the tumor necrosis factor receptor superfamily complex, is a central cellular component that converts TNF superfamily ligand signals into diverse immune and cell fate outcomes. Its compositional flexibility and adaptor-dependent signaling make it a rich area for mechanistic and translational research. CRISPR-based models provide a direct route to test the causal roles of individual receptors and adaptors in health and disease.
References
- 1. Idriss HT et al.. 2000. TNF alpha and the TNF receptor superfamily: structure-function relationship(s).. Microsc Res Tech 50(3):184-95 PMID: 10891884
- 2. Xu WD et al.. 2022. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.. Front Immunol 13:891328 PMID: 35911746
- 3. Muller J et al.. 2018. Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function.. Adv Immunol 140:21-57 PMID: 30366518
- 4. Glögl M et al.. 2024. Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists.. Science 386(6726):1154-1161 PMID: 39636970
- 5. Ababneh O et al.. 2024. Tumor necrosis factor superfamily signaling: life and death in cancer.. Cancer Metastasis Rev 43(4):1137-1163 PMID: 39363128
- 6. Wu H. 2004. Assembly of post-receptor signaling complexes for the tumor necrosis factor receptor superfamily.. Adv Protein Chem 68:225-79 PMID: 15500863
- 7. Naismith JH et al.. 1995. Tumor necrosis factor receptor superfamily.. J Inflamm 47(1-2):1-7 PMID: 8913924
- 8. Ellebrecht CT et al.. 2016. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.. Science 353(6295):179-84 PMID: 27365313
